FDA Pediatric Advisory Committee Endorses Routine Safety Monitoring for Antipsychotic Medications

Mergers & Acquisitions The U.S. Food and Drug Administration's (FDA) pediatric advisory committee voted to support the FDA's routine safety monitoring of the new generation of antipsychotics. They did so with a caveat that the agency specifically looks at how to clarify the drugs' labels to highlight concerns of their impact on children, namely the risks of weight gain and diabetes. The new generation of antipsychotic medications has raised a wave of concerns as they are increasingly being prescribed for a host of uses and for younger and younger patients, with little conclusive research addressing their impact . . .